A DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PLACEBO-CONTROLLED 10-WEEK STUDY ASSESSING THE EFFICACY AND SAFETY OF F2695 SR FLEXIBLE DOSE (75,100 MG /DAY) IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER EFFICACY AND TOLERANCE OF F2695 SR IN MAJOR DEPRESSIVE DISORDER

Trial Profile

A DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PLACEBO-CONTROLLED 10-WEEK STUDY ASSESSING THE EFFICACY AND SAFETY OF F2695 SR FLEXIBLE DOSE (75,100 MG /DAY) IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER EFFICACY AND TOLERANCE OF F2695 SR IN MAJOR DEPRESSIVE DISORDER

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2015

At a glance

  • Drugs Levomilnacipran (Primary)
  • Indications Major depressive disorder
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Pierre Fabre
  • Most Recent Events

    • 20 May 2015 Pooled analysis (recurrent and first episode MDD) results presented at the 168th Annual Meeting of the American Psychiatric Association.
    • 09 Oct 2013 Pooled results for patient subgroups from 5 trials presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
    • 09 Oct 2013 Pooled results from 5 trials presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top